Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 2
2007 2
2008 2
2009 7
2010 4
2011 7
2012 15
2013 5
2014 8
2015 13
2016 8
2017 11
2018 14
2019 4
2020 5
2021 11
2022 15
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
HDACi--targets beyond chromatin.
Buchwald M, Krämer OH, Heinzel T. Buchwald M, et al. Among authors: kramer oh. Cancer Lett. 2009 Aug 8;280(2):160-7. doi: 10.1016/j.canlet.2009.02.028. Epub 2009 Apr 1. Cancer Lett. 2009. PMID: 19342155 Review.
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer.
Schneeweis C, Diersch S, Hassan Z, Krauß L, Schneider C, Lucarelli D, Falcomatà C, Steiger K, Öllinger R, Krämer OH, Arlt A, Grade M, Schmidt-Supprian M, Hessmann E, Wirth M, Rad R, Reichert M, Saur D, Schneider G. Schneeweis C, et al. Among authors: kramer oh. Cell Mol Life Sci. 2022 Dec 19;80(1):12. doi: 10.1007/s00018-022-04638-y. Cell Mol Life Sci. 2022. PMID: 36534167 Free PMC article.
Concepts to Target MYC in Pancreatic Cancer.
Wirth M, Mahboobi S, Krämer OH, Schneider G. Wirth M, et al. Among authors: kramer oh. Mol Cancer Ther. 2016 Aug;15(8):1792-8. doi: 10.1158/1535-7163.MCT-16-0050. Epub 2016 Jul 12. Mol Cancer Ther. 2016. PMID: 27406986 Review.
HDAC2 Facilitates Pancreatic Cancer Metastasis.
Krauß L, Urban BC, Hastreiter S, Schneider C, Wenzel P, Hassan Z, Wirth M, Lankes K, Terrasi A, Klement C, Cernilogar FM, Öllinger R, de Andrade Krätzig N, Engleitner T, Schmid RM, Steiger K, Rad R, Krämer OH, Reichert M, Schotta G, Saur D, Schneider G. Krauß L, et al. Among authors: kramer oh. Cancer Res. 2022 Feb 15;82(4):695-707. doi: 10.1158/0008-5472.CAN-20-3209. Cancer Res. 2022. PMID: 34903606 Free PMC article.
Interstrand Crosslink Repair as a Target for HDAC Inhibition.
Nikolova T, Kiweler N, Krämer OH. Nikolova T, et al. Among authors: kramer oh. Trends Pharmacol Sci. 2017 Sep;38(9):822-836. doi: 10.1016/j.tips.2017.05.009. Epub 2017 Jul 4. Trends Pharmacol Sci. 2017. PMID: 28687272 Review.
Survivin and YM155: how faithful is the liaison?
Rauch A, Hennig D, Schäfer C, Wirth M, Marx C, Heinzel T, Schneider G, Krämer OH. Rauch A, et al. Among authors: kramer oh. Biochim Biophys Acta. 2014 Apr;1845(2):202-20. doi: 10.1016/j.bbcan.2014.01.003. Epub 2014 Jan 16. Biochim Biophys Acta. 2014. PMID: 24440709 Review.
Drugging the HDAC6-HSP90 interplay in malignant cells.
Krämer OH, Mahboobi S, Sellmer A. Krämer OH, et al. Trends Pharmacol Sci. 2014 Oct;35(10):501-9. doi: 10.1016/j.tips.2014.08.001. Epub 2014 Sep 16. Trends Pharmacol Sci. 2014. PMID: 25234862 Review.
Medicinal chemistry advances in targeting class I histone deacetylases.
Abdallah DI, de Araujo ED, Patel NH, Hasan LS, Moriggl R, Krämer OH, Gunning PT. Abdallah DI, et al. Among authors: kramer oh. Explor Target Antitumor Ther. 2023;4(4):757-779. doi: 10.37349/etat.2023.00166. Epub 2023 Aug 31. Explor Target Antitumor Ther. 2023. PMID: 37711592 Free PMC article. Review.
129 results